https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-03-13 11:24:402023-03-13 11:24:40ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-03-08 11:25:142023-03-13 11:26:06Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-28 10:10:452023-03-02 10:11:43Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-21 08:30:422023-02-22 10:34:10LEX Diagnostics Appoints Scott O’Brien as LEX Board Member
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-16 08:00:002023-02-21 13:41:11Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-14 08:00:092023-02-15 13:26:14Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-07 08:00:272023-02-07 14:45:37TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-01-17 10:39:112023-01-19 10:40:51GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-01-09 11:33:582023-01-19 11:30:48ExeVir Bio secures EUR 25 million venture debt financing from European Investment Bank
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-01-09 07:03:472023-01-19 11:31:00BC Platforms Selected as Partner to deliver key Singapore Population Health Study
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-12-21 11:16:102023-01-19 11:31:06Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-12-01 09:34:262023-01-19 11:31:46Partnership of BC Platforms, Euformatics and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-24 10:16:092023-01-19 11:31:57BC Platforms Partners with EU Funded, AI-Driven Cancer Data Initiative
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-10 11:24:252022-11-16 15:48:09EnteroBiotix partners with Imperial College London to advance microbiome therapeutics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-09 11:39:522022-11-16 15:54:32BC Platforms Announces Powerful Patient Data Sharing Platform to speed up Biotech R&D Process
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-09 08:47:472022-11-16 15:55:39TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US Helsinki, Finland
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-08 10:28:592022-11-16 15:53:08BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-03 11:15:412022-11-16 15:52:43CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-10-13 09:04:482022-11-16 15:52:29AdAlta and GPCR Therapeutics collaborate on novel cancer therapeutics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-10-12 12:11:142022-11-16 15:51:57SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-10-11 09:57:262022-11-16 15:51:32TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-09-12 11:38:372022-09-27 11:48:57SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-09-07 11:27:112022-09-27 11:32:07GPCR Therapeutics Expands US Facilities with Relocation to Redwood City
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-07-26 10:02:062022-09-27 11:33:41Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-30 13:01:172022-07-04 13:01:33EnteroBiotix Appoints David Lawrence to its Board of Directors
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-27 09:00:062022-06-27 16:20:33Valo Therapeutics Appoints Experienced Life Sciences Executive Anthony Giovinazzo to Board
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-16 11:22:562022-06-21 11:24:08Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-08 10:45:182022-06-10 12:04:39Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-06 12:38:182022-06-10 12:04:01Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-06 11:24:482022-06-06 11:33:07BC Platforms Drives Data Enablement and Collaboration to Accelerate Precision Medicine in Asia
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-05-26 09:05:512022-06-01 11:59:21Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-05-18 09:04:582022-05-31 09:02:54BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-05-13 09:44:432022-05-13 09:44:43BC Platforms Announces Partnerships with Three Finnish Biobanks to Advance Novel Diagnostics and Treatments
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-04-25 10:43:152022-04-25 10:43:15Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-04-21 16:18:432022-04-22 16:19:11EIB provides €15 million to fund coronavirus research at IRBM
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-03-31 15:52:402022-04-08 15:56:16TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-03-15 09:22:562022-03-16 09:23:10Etcembly Appoints Scott Cuthill as Chief Business Officer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-02-21 13:42:492022-02-21 13:42:49BC Platforms Adds Japan’s Mitsubishi Space Software to its Global Data Network
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-02-09 15:36:192022-02-10 15:39:16Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix™ Product Platform
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-27 15:31:432022-02-10 15:35:28SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-18 15:10:052022-01-18 15:10:05Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-06 10:15:582022-01-10 10:20:28Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-20 12:05:302022-01-10 12:06:12Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-17 15:15:152022-01-10 15:17:09BC Platforms Delivers on Global Real-World Data and Platform Access
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-13 11:58:302022-01-10 12:09:41Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-06 12:16:132022-01-10 12:17:21Amphista Therapeutics Appoints Dr Martin Pass as CDO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-15 08:23:042022-01-10 10:25:08Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-12 16:14:242021-11-12 16:14:24Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-09 10:17:122021-11-09 10:17:12Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-04 10:12:262021-11-09 10:14:58SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-04 10:08:472021-11-09 10:09:56Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-10-27 13:46:322022-04-22 16:15:19EnteroBiotix Expands Headcount and Premises to Advance Microbiome Drug Pipeline
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-10-20 13:33:432021-10-27 13:33:55BC Platforms Expands Partnership with Thailand’s Bumrungrad International Hospital to Accelerate Adoption of Precision Medicine in Southeast Asia
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-10-14 13:51:192021-10-27 13:51:48Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-09-13 08:26:472021-09-13 08:26:47BC Platforms to Enable Longitudinal RWD and Genomics Access for Drug Development in Africa
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-09-08 09:51:042021-09-08 09:51:04Anocca appoints Jacob Michlewicz as CFO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-09-07 12:56:362021-09-07 16:35:20EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-08-27 13:25:512021-09-08 09:42:28TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-22 06:41:042021-07-22 06:41:04Anocca raises $47m in a Series B Financing to advance its industrialised approach to TCR-T cellular immunotherapy
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-14 09:03:422021-08-05 16:13:58Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-13 10:41:482021-07-13 10:41:48Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-08 16:02:062021-08-05 16:13:25Vaccitech to Present at the William Blair Biotech Focus Conference 2021
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-07 10:55:462021-07-07 10:55:46Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-06 13:08:012021-07-06 13:08:12Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-06-28 15:39:372021-07-06 13:08:27Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-06-18 13:14:132021-07-06 13:08:47BC Platforms Announces CureDuchenne Collaboration to Promote Critical Research & Accelerate Drug Development
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-06-14 13:11:052021-07-06 13:09:07TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-12 08:15:352021-05-12 08:15:35New BC Platforms Partnership with Artisan Biomed to Unlock African Access to Precision Medicine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-11 10:24:402021-05-12 10:24:55Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-11 08:56:582021-05-11 08:57:07Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-06 16:35:202021-05-11 08:55:11Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-05 14:29:202021-05-05 14:29:20Vaccitech Announces Closing of $110.5 Million Initial Public Offering
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-05 08:44:222021-05-05 08:44:22TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital open cancer immunotherapy clinical trial
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-30 08:08:562021-04-30 08:09:15Vaccitech Announces Pricing of Initial Public Offering
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-26 10:41:522021-04-26 10:41:52BC Platforms Partnership to Drive New UK Health Data Research Tool
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-20 11:09:412021-04-21 11:12:35BC Platforms Partners with TripleBlind to Power Federated Artificial Intelligence (AI) Data Privacy Approaches
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-19 10:40:432021-04-19 10:40:43Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-13 09:46:412021-04-13 09:47:01BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-22 08:24:112021-03-22 08:24:48Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-18 08:21:572021-03-22 08:25:06Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-17 12:49:182021-03-17 12:49:18Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-17 07:15:042021-03-17 07:15:04Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-15 14:19:482021-03-15 14:19:48TILT Biotherapeutics advances cancer immunotherapy clinical trial achieving primary end point in the first cohort
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-09 11:27:062021-03-11 11:28:53Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-08 09:29:242021-03-08 09:29:24Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-23 08:00:042021-03-02 08:27:12BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-18 07:00:122021-02-18 11:25:41Advent Life Sciences Announces Close of Two New Funds Totalling $215 million
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-01 08:00:462021-02-01 09:14:55Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-01 08:00:082021-02-01 09:14:27X-Bolt Features in Largest Ever Hip Fracture Fixation Trial Publication
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-01-26 08:00:362021-01-26 08:42:17BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-01-21 08:00:342021-01-26 08:42:47Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-01-19 12:00:292021-01-21 11:06:25InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2021-01-07 14:10:542021-01-09 17:27:10Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-30 14:13:122021-01-08 14:18:15Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-18 17:10:092021-01-20 17:28:37BC Platforms delivers data platform for UK research consortium to improve detection of lung cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-17 17:24:302021-01-09 17:37:15BC Platforms Rings in an Award-Winning Year with record growth in its BCRQUEST.com global data partner network and BC|INSIGHT Discovery and Research platform
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-11-23 11:38:022020-12-01 11:38:36Oxford University breakthrough on global COVID-19 vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-28 11:46:252020-12-01 11:48:18BC Platforms Announces Partnership with CO-CONNECT Consortium to accelerate COVID-19 research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-20 10:21:252020-10-20 10:21:25Vaccitech expands management team with hires including CMO and CFO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-01 15:02:302020-10-20 10:24:13BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network BCRQUEST.com to advance Personalized Healthcare Research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-09-21 15:37:302020-09-22 15:44:54Theolytics Announces Appointment of Immatics’ Carsten Reinhardt to its Board of Directors
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-09-16 15:12:162020-09-22 15:29:07Pneumagen Announces Scientific Advisory Board and Development Team Appointments
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-08-03 16:59:342020-08-13 09:16:43Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-07-21 14:28:132020-08-13 09:16:09IRBM to collaborate with MSD to develop peptides against coronavirus
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-06-23 12:15:122020-06-30 21:08:15First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-06-16 10:14:462020-07-02 10:22:09TILT Biotherapeutics secures over EUR 6 million to advance cancer immunotherapies into clinic
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-28 12:17:592020-06-30 21:13:40IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-27 12:24:302020-06-30 21:12:03Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-21 09:00:162020-06-30 21:01:18Amphista Therapeutics appoints Ian Churcher as CSO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-19 17:46:352020-06-23 15:48:41BC Platforms and Kaiser Permanente Win 2020 Microsoft Health Innovation Award for Precision Medicine Collaboration
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-08 12:25:082020-06-30 21:11:51Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-30 09:00:082020-06-30 21:07:49Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-27 12:30:062020-06-30 21:03:44Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-22 12:30:582020-06-30 21:03:28Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-07 09:00:412020-06-30 20:59:10Amphista Therapeutics raises $7.5m Series A round
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-06 17:47:232020-06-23 15:49:16World’s leading biobanks join BC Platforms’ Global Data Partner Network to advance personalized healthcare research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-03-23 09:00:112020-06-30 20:57:12Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-03-06 17:48:042020-06-23 15:48:21BC Platforms Appoints Board Member Karen Tay Koh to Accelerate Asia Growth
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-02-28 12:01:482020-07-02 10:27:25FinnGen Grows to One of the Largest Private-Public Studies in the World
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-02-07 12:18:352020-07-02 10:25:09The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-02-06 12:32:272020-06-30 21:02:39Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-01-31 12:33:092020-06-30 21:02:06Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-01-08 12:11:172020-06-30 21:15:28BC Platforms partners with Dante Labs to build Europe’s largest Next Generation Sequencing laboratory for private and public customers
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2019-12-18 12:12:102020-06-30 21:14:18BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA to Extend Data Analytics in Genomics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2019-11-12 12:27:152020-06-30 21:08:56Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2019-09-09 12:19:472020-06-30 21:12:25IRBM signs agreement with MD Anderson Cancer Center to generate novel immune-checkpoint monoclonal antibodies.
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2018-11-24 12:20:592020-06-30 21:12:14CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-06 12:16:132022-01-10 12:17:21Amphista Therapeutics Appoints Dr Martin Pass as CDO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-06-28 15:39:372021-07-06 13:08:27Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-17 07:15:042021-03-17 07:15:04Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-21 09:00:162020-06-30 21:01:18Amphista Therapeutics appoints Ian Churcher as CSO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-07 09:00:412020-06-30 20:59:10Amphista Therapeutics raises $7.5m Series A round
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-12-21 11:16:102023-01-19 11:31:06Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-09 10:17:122021-11-09 10:17:12Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-09-08 09:51:042021-09-08 09:51:04Anocca appoints Jacob Michlewicz as CFO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-22 06:41:042021-07-22 06:41:04Anocca raises $47m in a Series B Financing to advance its industrialised approach to TCR-T cellular immunotherapy
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-01-09 07:03:472023-01-19 11:31:00BC Platforms Selected as Partner to deliver key Singapore Population Health Study
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-12-01 09:34:262023-01-19 11:31:46Partnership of BC Platforms, Euformatics and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-24 10:16:092023-01-19 11:31:57BC Platforms Partners with EU Funded, AI-Driven Cancer Data Initiative
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-09 11:39:522022-11-16 15:54:32BC Platforms Announces Powerful Patient Data Sharing Platform to speed up Biotech R&D Process
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-08 10:28:592022-11-16 15:53:08BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-06 11:24:482022-06-06 11:33:07BC Platforms Drives Data Enablement and Collaboration to Accelerate Precision Medicine in Asia
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-05-18 09:04:582022-05-31 09:02:54BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-05-13 09:44:432022-05-13 09:44:43BC Platforms Announces Partnerships with Three Finnish Biobanks to Advance Novel Diagnostics and Treatments
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-02-21 13:42:492022-02-21 13:42:49BC Platforms Adds Japan’s Mitsubishi Space Software to its Global Data Network
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-17 15:15:152022-01-10 15:17:09BC Platforms Delivers on Global Real-World Data and Platform Access
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-10-20 13:33:432021-10-27 13:33:55BC Platforms Expands Partnership with Thailand’s Bumrungrad International Hospital to Accelerate Adoption of Precision Medicine in Southeast Asia
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-09-13 08:26:472021-09-13 08:26:47BC Platforms to Enable Longitudinal RWD and Genomics Access for Drug Development in Africa
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-06-18 13:14:132021-07-06 13:08:47BC Platforms Announces CureDuchenne Collaboration to Promote Critical Research & Accelerate Drug Development
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-12 08:15:352021-05-12 08:15:35New BC Platforms Partnership with Artisan Biomed to Unlock African Access to Precision Medicine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-26 10:41:522021-04-26 10:41:52BC Platforms Partnership to Drive New UK Health Data Research Tool
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-20 11:09:412021-04-21 11:12:35BC Platforms Partners with TripleBlind to Power Federated Artificial Intelligence (AI) Data Privacy Approaches
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-13 09:46:412021-04-13 09:47:01BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-23 08:00:042021-03-02 08:27:12BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-01-26 08:00:362021-01-26 08:42:17BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2021-01-07 14:10:542021-01-09 17:27:10Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-18 17:10:092021-01-20 17:28:37BC Platforms delivers data platform for UK research consortium to improve detection of lung cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-17 17:24:302021-01-09 17:37:15BC Platforms Rings in an Award-Winning Year with record growth in its BCRQUEST.com global data partner network and BC|INSIGHT Discovery and Research platform
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-28 11:46:252020-12-01 11:48:18BC Platforms Announces Partnership with CO-CONNECT Consortium to accelerate COVID-19 research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-01 15:02:302020-10-20 10:24:13BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network BCRQUEST.com to advance Personalized Healthcare Research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-19 17:46:352020-06-23 15:48:41BC Platforms and Kaiser Permanente Win 2020 Microsoft Health Innovation Award for Precision Medicine Collaboration
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-06 17:47:232020-06-23 15:49:16World’s leading biobanks join BC Platforms’ Global Data Partner Network to advance personalized healthcare research
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-03-06 17:48:042020-06-23 15:48:21BC Platforms Appoints Board Member Karen Tay Koh to Accelerate Asia Growth
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-02-28 12:01:482020-07-02 10:27:25FinnGen Grows to One of the Largest Private-Public Studies in the World
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-01-08 12:11:172020-06-30 21:15:28BC Platforms partners with Dante Labs to build Europe’s largest Next Generation Sequencing laboratory for private and public customers
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2019-12-18 12:12:102020-06-30 21:14:18BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA to Extend Data Analytics in Genomics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-08 10:45:182022-06-10 12:04:39Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-04-21 16:18:432022-04-22 16:19:11EIB provides €15 million to fund coronavirus research at IRBM
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-07-21 14:28:132020-08-13 09:16:09IRBM to collaborate with MSD to develop peptides against coronavirus
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-28 12:17:592020-06-30 21:13:40IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-02-07 12:18:352020-07-02 10:25:09The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2019-09-09 12:19:472020-06-30 21:12:25IRBM signs agreement with MD Anderson Cancer Center to generate novel immune-checkpoint monoclonal antibodies.
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2018-11-24 12:20:592020-06-30 21:12:14CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-08 09:29:242021-03-08 09:29:24Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-01-21 08:00:342021-01-26 08:42:47Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-09-16 15:12:162020-09-22 15:29:07Pneumagen Announces Scientific Advisory Board and Development Team Appointments
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-27 12:24:302020-06-30 21:12:03Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-05-08 12:25:082020-06-30 21:11:51Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2019-11-12 12:27:152020-06-30 21:08:56Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-06 12:38:182022-06-10 12:04:01Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-18 15:10:052022-01-18 15:10:05Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-13 11:58:302022-01-10 12:09:41Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-12 16:14:242021-11-12 16:14:24Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-04 10:08:472021-11-09 10:09:56Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-08 16:02:062021-08-05 16:13:25Vaccitech to Present at the William Blair Biotech Focus Conference 2021
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-06 13:08:012021-07-06 13:08:12Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-05 14:29:202021-05-05 14:29:20Vaccitech Announces Closing of $110.5 Million Initial Public Offering
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-30 08:08:562021-04-30 08:09:15Vaccitech Announces Pricing of Initial Public Offering
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-22 08:24:112021-03-22 08:24:48Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-18 08:21:572021-03-22 08:25:06Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-17 12:49:182021-03-17 12:49:18Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-01 08:00:462021-02-01 09:14:55Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-30 14:13:122021-01-08 14:18:15Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-11-23 11:38:022020-12-01 11:38:36Oxford University breakthrough on global COVID-19 vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-20 10:21:252020-10-20 10:21:25Vaccitech expands management team with hires including CMO and CFO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-06-23 12:15:122020-06-30 21:08:15First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-30 09:00:082020-06-30 21:07:49Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-03-23 09:00:112020-06-30 20:57:12Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-16 08:00:002023-02-21 13:41:11Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-14 08:00:092023-02-15 13:26:14Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-07-26 10:02:062022-09-27 11:33:41Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-27 09:00:062022-06-27 16:20:33Valo Therapeutics Appoints Experienced Life Sciences Executive Anthony Giovinazzo to Board
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-06-16 11:22:562022-06-21 11:24:08Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-06 10:15:582022-01-10 10:20:28Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-11-15 08:23:042022-01-10 10:25:08Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-13 10:41:482021-07-13 10:41:48Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-19 10:40:432021-04-19 10:40:43Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-09 11:27:062021-03-11 11:28:53Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-08-03 16:59:342020-08-13 09:16:43Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-27 12:30:062020-06-30 21:03:44Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-04-22 12:30:582020-06-30 21:03:28Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-02-06 12:32:272020-06-30 21:02:39Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-01-31 12:33:092020-06-30 21:02:06Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-07 08:00:272023-02-07 14:45:37TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-11-09 08:47:472022-11-16 15:55:39TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US Helsinki, Finland
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2022-10-11 09:57:262022-11-16 15:51:32TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-03-31 15:52:402022-04-08 15:56:16TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-08-27 13:25:512021-09-08 09:42:28TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-06-14 13:11:052021-07-06 13:09:07TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-05 08:44:222021-05-05 08:44:22TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital open cancer immunotherapy clinical trial
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-15 14:19:482021-03-15 14:19:48TILT Biotherapeutics advances cancer immunotherapy clinical trial achieving primary end point in the first cohort
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00luminaryhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngluminary2020-06-16 10:14:462020-07-02 10:22:09TILT Biotherapeutics secures over EUR 6 million to advance cancer immunotherapies into clinic
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-12-20 12:05:302022-01-10 12:06:12Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2021-10-14 13:51:192021-10-27 13:51:48Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-14 09:03:422021-08-05 16:13:58Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-11 10:24:402021-05-12 10:24:55Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-06 16:35:202021-05-11 08:55:11Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2023-02-28 10:10:452023-03-02 10:11:43Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-07 10:55:462021-07-07 10:55:46Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-11 08:56:582021-05-11 08:57:07Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug
GPCR Therapeutics Announces Publication in Nature Scientific Reports on Novel Anticancer Therapy
Read full release
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
Read full release
MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director.
Read full release
Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
Read full release
Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
Read full release
LEX Diagnostics Appoints Scott O’Brien as LEX Board Member
Read full release
Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
Read full release
Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology
Read full release
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
Read full release
GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma
Read full release
LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer
Read full release
Valo Therapeutics selects Exothera to develop large scale oncolytic Adenovirus manufacturing
Read full release
ExeVir Bio secures EUR 25 million venture debt financing from European Investment Bank
Read full release
BC Platforms Selected as Partner to deliver key Singapore Population Health Study
Read full release
Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer
Read full release
Etcembly Announces Breakthrough in Optimising TCR Assets
Read full release
Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as Novel Metabolic Immune Checkpoint
Read full release
Partnership of BC Platforms, Euformatics and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals
Read full release
BC Platforms Partners with EU Funded, AI-Driven Cancer Data Initiative
Read full release
EnteroBiotix partners with Imperial College London to advance microbiome therapeutics
Read full release
BC Platforms Announces Powerful Patient Data Sharing Platform to speed up Biotech R&D Process
Read full release
TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US Helsinki, Finland
Read full release
BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
Read full release
BC Platforms Announces Partnership With CENTOGENE to Enable Access to Data-Driven Insights
Read full release
CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial
Read full release
AdAlta and GPCR Therapeutics collaborate on novel cancer therapeutics
Read full release
SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
Read full release
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
Read full release
EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics
Read full release
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
Read full release
SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
Read full release
GPCR Therapeutics Expands US Facilities with Relocation to Redwood City
Read full release
Valo Therapeutics Announces Scientific Advisory Board
Read full release
Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies
Read full release
Orthox Announces MHRA Authorisation for Clinical Trial of Knee Cartilage Repair FibroFix™ Product Platform
Read full release
EnteroBiotix Appoints David Lawrence to its Board of Directors
Read full release
Valo Therapeutics Appoints Experienced Life Sciences Executive Anthony Giovinazzo to Board
Read full release
Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer
Read full release
TILT Biotherapeutics Announces over $10 Million Financing to Advance Oncology Immunotherapy Assets
Read full release
Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.
Read full release
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Read full release
BC Platforms Drives Data Enablement and Collaboration to Accelerate Precision Medicine in Asia
Read full release
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Read full release
BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals
Read full release
BC Platforms Announces Partnerships with Three Finnish Biobanks to Advance Novel Diagnostics and Treatments
Read full release
GPCR Therapeutics Expands Scientific Advisory Board
Read full release
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Read full release
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
Read full release
EIB provides €15 million to fund coronavirus research at IRBM
Read full release
Renowned Immunotherapy Expert Dr. Michael Kalos Joins Anocca’s Scientific Advisory Board
Read full release
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
Read full release
Oppilotech and Evariste Technologies Announce Partnership to Develop First-in-Class Antibacterial Programme
Read full release
Etcembly Appoints Scott Cuthill as Chief Business Officer
Read full release
BC Platforms Adds Japan’s Mitsubishi Space Software to its Global Data Network
Read full release
Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix™ Product Platform
Read full release
SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor
Read full release
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
Read full release
Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment
Read full release
Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China
Read full release
BC Platforms Delivers on Global Real-World Data and Platform Access
Read full release
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
Read full release
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
Read full release
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Read full release
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
Read full release
Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO
Read full release
Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
Read full release
Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
Read full release
Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development
Read full release
SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies
Read full release
Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
Read full release
Amphista Therapeutics Appoints CBO, Beverley Carr
Read full release
EnteroBiotix Expands Headcount and Premises to Advance Microbiome Drug Pipeline
Read full release
BC Platforms Expands Partnership with Thailand’s Bumrungrad International Hospital to Accelerate Adoption of Precision Medicine in Southeast Asia
Read full release
Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy
Read full release
VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform
Read full release
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
Read full release
BC Platforms to Enable Longitudinal RWD and Genomics Access for Drug Development in Africa
Read full release
Anocca appoints Jacob Michlewicz as CFO
Read full release
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
Read full release
Vaccitech to join Brookfield’s Harwell Campus
Read full release
Vaccitech Oncology Limited’s ChAdOx1/MVA prime-boost immunotherapeutic shows preclinical potential as a novel cancer treatment
Read full release
BC Platforms Launches packaged end-to-end solution for NGS laboratories with Sentieon to accelerate adoption of NGS testing
Read full release
TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
Read full release
Anocca raises $47m in a Series B Financing to advance its industrialised approach to TCR-T cellular immunotherapy
Read full release
Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
Read full release
Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
Read full release
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
Read full release
Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia
Read full release
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
Read full release
Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
Read full release
BC Platforms Announces CureDuchenne Collaboration to Promote Critical Research & Accelerate Drug Development
Read full release
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
Read full release
New BC Platforms Partnership with Artisan Biomed to Unlock African Access to Precision Medicine
Read full release
Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer
Read full release
Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug
Read full release
Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19
Read full release
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
Read full release
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital open cancer immunotherapy clinical trial
Read full release
Vaccitech Announces Pricing of Initial Public Offering
Read full release
BC Platforms Partnership to Drive New UK Health Data Research Tool
Read full release
BC Platforms Partners with TripleBlind to Power Federated Artificial Intelligence (AI) Data Privacy Approaches
Read full release
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Read full release
BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes
Read full release
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
Read full release
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
Read full release
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
Read full release
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Read full release
TILT Biotherapeutics advances cancer immunotherapy clinical trial achieving primary end point in the first cohort
Read full release
Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine
Read full release
Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
Read full release
BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research
Read full release
Advent Life Sciences Announces Close of Two New Funds Totalling $215 million
Read full release
Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline
Read full release
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
Read full release
X-Bolt Features in Largest Ever Hip Fracture Fixation Trial Publication
Read full release
BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19
Read full release
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
Read full release
InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19
Read full release
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
Read full release
Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
Read full release
BC Platforms delivers data platform for UK research consortium to improve detection of lung cancer
Read full release
BC Platforms Rings in an Award-Winning Year with record growth in its BCRQUEST.com global data partner network and BC|INSIGHT Discovery and Research platform
Read full release
Oxford University breakthrough on global COVID-19 vaccine
Read full release
BC Platforms Announces Partnership with CO-CONNECT Consortium to accelerate COVID-19 research
Read full release
Vaccitech expands management team with hires including CMO and CFO
Read full release
BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network BCRQUEST.com to advance Personalized Healthcare Research
Read full release
Theolytics Announces Appointment of Immatics’ Carsten Reinhardt to its Board of Directors
Read full release
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
Read full release
Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO
Read full release
IRBM to collaborate with MSD to develop peptides against coronavirus
Read full release
Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response
Read full release
First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
Read full release
TILT Biotherapeutics secures over EUR 6 million to advance cancer immunotherapies into clinic
Read full release
Valo Therapeutics Announces Board Appointment of Dr Mai-Britt Zocca
Read full release
IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
Read full release
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
Read full release
Amphista Therapeutics appoints Ian Churcher as CSO
Read full release
BC Platforms and Kaiser Permanente Win 2020 Microsoft Health Innovation Award for Precision Medicine Collaboration
Read full release
Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
Read full release
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Read full release
Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Read full release
Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine
Read full release
Oxford COVID-19 vaccine begins human trial stage
Read full release
Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology
Read full release
Amphista Therapeutics raises $7.5m Series A round
Read full release
World’s leading biobanks join BC Platforms’ Global Data Partner Network to advance personalized healthcare research
Read full release
Vaccitech to Present at Solebury Trout Virtual Investor Conference
Read full release
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Read full release
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Read full release
BC Platforms Appoints Board Member Karen Tay Koh to Accelerate Asia Growth
Read full release
FinnGen Grows to One of the Largest Private-Public Studies in the World
Read full release
The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
Read full release
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Read full release
Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards
Read full release
Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
Read full release
BC Platforms partners with Dante Labs to build Europe’s largest Next Generation Sequencing laboratory for private and public customers
Read full release
BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA to Extend Data Analytics in Genomics
Read full release
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Read full release
IRBM signs agreement with MD Anderson Cancer Center to generate novel immune-checkpoint monoclonal antibodies.
Read full release
CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
Read full release